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Abstract
While numerous studies have implicated copy number variants (CNVs) in a range of neurological phenotypes, the impact
relative to disease severity has been difficult to ascertain due to small sample sizes, lack of phenotypic details, and
heterogeneity in platforms used for discovery. Using a customized microarray enriched for genomic hotspots, we assayed
for large CNVs among 1,227 individuals with various neurological deficits including dyslexia (376), sporadic autism (350), and
intellectual disability (ID) (501), as well as 337 controls. We show that the frequency of large CNVs (.1 Mbp) is significantly
greater for ID–associated phenotypes compared to autism (p = 9.58610211, odds ratio = 4.59), dyslexia (p = 3.81610218,
odds ratio = 14.45), or controls (p = 2.75610217, odds ratio = 13.71). There is a striking difference in the frequency of rare
CNVs (.50 kbp) in autism (10%, p = 2.461026, odds ratio = 6) or ID (16%, p = 3.55610212, odds ratio = 10) compared to
dyslexia (2%) with essentially no difference in large CNV burden among dyslexia patients compared to controls. Rare CNVs
were more likely to arise de novo (64%) in ID when compared to autism (40%) or dyslexia (0%). We observed a significantly
increased large CNV burden in individuals with ID and multiple congenital anomalies (MCA) compared to ID alone
(p = 0.001, odds ratio = 2.54). Our data suggest that large CNV burden positively correlates with the severity of childhood
disability: ID with MCA being most severely affected and dyslexics being indistinguishable from controls. When autism
without ID was considered separately, the increase in CNV burden was modest compared to controls (p = 0.07, odds
ratio = 2.33).
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Introduction
Recent studies have implicated large, rare CNVs in a range of
neurodevelopmental disorders including intellectual disability (ID)
[1,2], autism [3,4], schizophrenia [5,6], bipolar disorder [7,8],
epilepsy [9,10], and attention deficit hyperactivity disorder
(ADHD) [11,12]. Several themes have emerged from these studies:
first, a significant enrichment for rare CNVs in individuals with
the disease compared to unaffected controls was observed,
independently, for each of these disorders; second, the same
recurrent CNVs are associated with different neuropsychiatric
phenotypes; and third, locus heterogeneity is substantial as many
distinct variants can lead to similar phenotypes.
Our understanding of the relevance of rare CNVs across a
broad spectrum of neurodevelopmental disorders, varying in
severity and prevalence, is limited as previous studies were
restricted to the analysis of one phenotype at a time and each of
such studies was performed using different CNV genotyping
methodologies with distinct platform-specific biases, making
comparisons difficult. We undertook a systematic analysis of
1,227 cases and 337 controls to assess the relative contribution of
CNVs in three phenotypically distinct neurodevelopmental
disorders. We designed a whole-genome custom microarray
targeted to genomic hotspots for comparative genomic hybridiza-
tion (CGH) to identify potentially pathogenic CNVs that
contribute to ID, autism, and dyslexia.
Results
We analyzed 1,227 individuals ascertained for three neurode-
velopmental disorders: 376 dyslexic children with a verbal IQ
(VIQ) $90 on the Wechsler Intelligence Scale for Children [13]
and dyslexia defined as poor performance and IQ-performance
discrepancy in one or more of a set of standardized reading
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measures, 350 cases with sporadic autism from the Simons
Simplex Collection (SSC), and 501 cases with ID. We used 337
NIMH control individuals for comparison. Further, based on the
presence or absence of ID (full-scale IQ score cutoff of 70), autism
cases were divided into those with ID (n= 97) or without ID
(n = 253) (see Materials and Methods). Based on the presence of
multiple congenital anomalies (MCA), individuals with ID were
divided into those with ID only—i.e. idiopathic ID (n= 428)—and
those with ID and MCA (n= 73).
All copy number variation analyses were performed using a
custom microarray with a high probe density (,2.6 kbp) targeted
to 107 genomic hotspot regions [14] (,251 Mbp) and a median
probe spacing of ,36 kbp in the genomic backbone (see Materials
and Methods, Table S1). We used a Hidden Markov Model
(HMM)-based algorithm to identify deletions and duplications. We
restricted our analysis to CNVs .50 kbp in size to reduce false
positive calls and validated all relevant CNVs using a second
custom designed high-density array. To empirically determine the
validation rate of the array at different genomic regions, we
examined 118 CNVs detected in 24 samples and confirmed 117
events (.99% accuracy, see Table S2). While we were easily able
to detect smaller events in the hotspot regions, the specificity of the
array restricted our CNV discovery to .50 kbp in hotspot-
associated regions and to .300 kbp in regions not associated with
genomic hotspots (Figure S1).
Analysis for large CNV burden in neurodevelopmental
phenotypes
After quality control (QC) filtering and manual curation, we
obtained 5,086 CNVs in 1,395 out of 1,564 individuals (89.2%)
with high-quality array CGH data (Table 1; Datasets S1, S2, S3,
S4). Using these data, we compared the CNV enrichment between
the multiple cohorts tested. We found a significant excess of large
CNVs (.1 Mbp) in individuals with ID (p = 2.75610217, odds
ratio = 13.71) or autism (p= 0.012, odds ratio = 2.99) when
compared to controls analyzed on the same microarray platform
(Figure 1). The frequency of large CNVs among children with
dyslexia was similar to controls (p = 0.64, odds ratio = 0.94),
although this might indicate a lack of statistical power in our study
to detect any subtle enrichment (power .0.8 to detect 4.2%
increase in burden) for large CNVs in dyslexia.
Within the neurodevelopmental disorder cohorts, a comparison
showed a significantly greater large CNV burden in individuals
with ID compared to autism (p= 9.58610211, odds ratio = 4.58)
or dyslexia (p = 3.81610218, odds ratio = 14.45). When we
partitioned the ID cohort into subsets with and without MCA,
we observed a significantly increased large CNV burden in
individuals with ID/MCA compared to ID alone (p= 0.001, odds
ratio = 2.54). This trend was also observed when individuals with
autism were separated into those with ID and without ID
(Figure 1), although not statistically significant (p = 0.102, odds
ratio = 2.1). When compared to controls, we noted a trend for
increase in large CNV burden for autism without ID (p = 0.07,
odds ratio = 2.33) as well as autism with ID (p = 0.0048, odds
ratio = 4.85). In addition, a gene-based analysis showed an
incremental increase in the proportion of disrupted genes and
average gene density per CNV with higher estimates for the ID/
MCA cohort as compared to ID alone or autism (Table 1). We
also note that within the cohorts no bias towards deletions or
duplications was observed in relation to phenotypic severity or
variability (Tables S3, S4, S5, S6, S7). Overall, our results suggest
a positive correlation of the severity of the phenotype to the size
and gene density of CNVs.
Rare CNVs in dyslexia, autism, and intellectual disability
phenotypes
To identify rare CNVs of likely pathogenic significance, we
compared the pattern of CNVs from dyslexia, autism, ID, and
NIMH control cohorts to a map developed from an expanded set
of 8,329 normal individuals genotyped with Illumina micro-
arrays and to the publicly available Database of Genomic
Variants [15] (see Materials and Methods). We eliminated
common copy number polymorphisms and CNVs from our cases
if they had a reciprocal overlap of 50% or more of their length
with CNVs found in these 8,329 controls. After filtering, we
compared the groups. We found a significant increase of rare
CNVs in individuals with autism (35/336, 10%; p = 2.461026,
odds ratio = 6) or ID (69/431, 16%; p = 3.55610212, odds
ratio = 10) compared to individuals with dyslexia (6/322, 2%)
(Figure 2A, Table 2). In fact, when analyzed separately, the
frequency of rare CNVs in NIMH controls (6/306, 2%) was not
different compared to dyslexia (p = 0.57, odds ratio = 0.94)
(Table S8).
Given the high population prevalence of dyslexia [16], we then
relaxed our selection to include events present at an allele
frequency of ,0.1% in controls (8/8,635) and identified four
additional CNVs—i.e., a total of 10 CNV events (Table 3). The
analysis of hotspot regions identified only one individual with
dyslexia who carried a 15q11.2 BP1–BP2 deletion, which has
previously been associated with ID [17], schizophrenia [18,19],
and epilepsy [20]; however, this deletion was also observed in
25/8,635 of our total control individuals. None of the seven
deletions and three duplications detected in our dyslexia cohort
mapped to candidate loci known to be associated with dyslexia
[21].
Analysis of 336 individuals from the SSC autism cohort showed
that 35 individuals (10%) carried 36 rare CNVs (680 RefSeq genes,
median size= 662 kbp) and about 58% (21/36) of these CNVs
mapped to genomic hotspots (Table 2). Only eight of the events (all
hotspot sites) associated with genomic disorders, including 22q11.2
deletion (TBX1, DiGeorge syndrome), 17p12 duplication (PMP22,
Author Summary
Deletions and duplications, termed copy number variants
(CNVs), have been implicated in a variety of neurodevel-
opmental disorders including intellectual disability (ID),
autism, and schizophrenia. Our understanding of the
relevance of large, rare CNVs in a range of neurodevelop-
mental phenotypes, varying in severity and prevalence,
has been difficult because these studies were restricted to
the analysis of one disorder at a time using different CNV
detection platforms, insufficient sample sizes, and a lack of
detailed clinical information. We tested 1,227 individuals
with different neurological diseases including dyslexia,
autism, and ID using the same CNV detection platform. We
observed striking differences in CNV burden and inheri-
tance characteristics among these cohorts and show that
ID is the primary correlate of large CNV burden. This
correlation is well illustrated by a comparison of autism
patients with and without ID—where the latter show only
modest increases in large CNV burden compared to
controls. We also find significant depletion in the
frequency of large CNVs in dyslexia compared to the
other cohorts. Further studies on larger sets of individuals
using high-resolution arrays and next-generation sequenc-
ing are warranted for a detailed understanding of the
relative contribution of genetic variants to neurodevelop-
mental disorders.
Large CNVs in Neurodevelopmental Phenotypes
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Charcot-Marie-Tooth disease), and 15q11.2q13.1 duplication
(UBE3A and SNRPN) (Table S9). In addition, as reported previously
[3,22,23], the autism-associated proximal 16p11.2 deletion (TBX6)
was observed in approximately 1% (3/336) of all autism cases
analyzed. Interestingly, one case with a de novo 16p11.2 deletion also
inherited a 2 Mbp duplication 22q11.2 (TBX1) from the mother.
Table 1. Summary of disease cohorts and CNV analysis.
All
Total
analyzed
Passed
QC
Total
CNVs
Average CNV
size (bp)
Proportion
of deletions
Proportion of CNVs
disrupting genes
Average
gene density
Controls 337 306 1,074 229,701 0.38 0.33 3.70
Dyslexia 376 322 1,041 217,135 0.37 0.34 3.82
Autism (no ID) 253 246 923 249,996 0.33 0.36 4.15
Autism (with ID) 97 90 362 342,637 0.41 0.33 4.95
Combined Autism 350 336 1,285 276,094 0.35 0.35 4.55
ID 428 358 1,306 442,519 0.33 0.38 6.12
ID/MCA 73 73 380 637,004 0.36 0.39 8.20
Combined ID cohort 501 431 1,686 486,353 0.34 0.38 7.16
For breaking genes, one or both of the CNV breakpoints should traverse a gene. CNV: Copy Number Variant; ID: Intellectual Disability; MCA: Multiple Congenital
Anomalies; QC: Quality Control.
doi:10.1371/journal.pgen.1002334.t001
Figure 1. CNV burden in neurodevelopmental disorders. (A) The figure shows the population frequency of the largest CNV (as a survivor
function) in individuals with ID, autism, dyslexia, and controls. (B) Population frequency of the largest CNV is shown for ID, ID with MCA, autism with
ID, autism without ID, dyslexia, and NIMH control individuals. (C) Histograms depicting deletions per individual at each size range are shown. Note
that 35 NIMH control samples carried an approximately 560 kbp deletion involving PRAME on distal 22q11.2. (D) Duplications per individual at each
size range are shown. The hotspot chip has higher coverage over segmental duplication regions and therefore there is an expected abundance of
duplications per individual compared to deletions.
doi:10.1371/journal.pgen.1002334.g001
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Among 431 cases with ID (358 cases with ID only and 73 cases
with ID plus MCA), 69 individuals carried 77 rare CNVs (2,215
RefSeq genes, median size = 1.5 Mbp) that were either of known
pathogenic significance or not observed in a total set of 8,635
controls, and 32% (25/77, median size = 1.42 Mbp) of these
variants localized to genomic hotspot regions (Table 2). This is a
significant enrichment for rare CNVs in the ID cohort compared
to autism (p = 0.019, odds ratio = 1.6) or dyslexia cohorts
(p = 3.55610212, odds ratio = 10). Interestingly, 20/77 CNVs (16
hotspot and four non-hotspot sites) mapped to a known genomic
Figure 2. Rare CNVs and de novo rates in neurodevelopmental disorders. (A) The proportion of rare CNVs as a function of size is shown for
NIMH controls and dyslexia, autism, and ID cohorts. To identify rare CNVs, we compared the pattern of CNVs from each of these cohorts to the CNV
frequency map from 8,329 controls genotyped on Illumina arrays. (B) The proportion of de novo occurrence of CNVs among the three cohorts is
shown for each size range. Note that the CNVs from the dyslexia cohort are all inherited. DNA from parents of NIMH controls was not available and
hence not tested for de novo CNV frequency.
doi:10.1371/journal.pgen.1002334.g002
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disorder site, including those associated with variable phenotypes
such as 15q13.1q13.3 (CHRNA7), 16p11.2 proximal (TBX6; two
cases) and distal (SH2B1) hotspots, 16p13.11 (MYH11; three cases),
17q12 (TCF2), and 3q29 (DLG1) as well as syndromic regions such
as 7q11.23 (Williams syndrome), 17q21.31 (MAPT), 5q35 (Sotos
syndrome), 8p23.1, 22q13 (Phelan-McDermid syndrome) [24] and
1p36 [25].
We next sought to determine whether these rare CNVs were
inherited or if they arose de novo in the probands. Parental DNA
samples were available to investigate inheritance for 90 out of 123
rare CNVs detected in all three disease cohorts (Table S8). In four
cases, only maternal DNA was available. We find that 44/90
CNVs arose de novo and a majority (77%, 34/44) of these de novo
CNVs were large (.1 Mbp). Overall, we find a greater proportion
of de novo events in ID (64%, 30/47) compared to autism (40%,
14/35; p= 0.027, odds ratio = 2.6) or dyslexia (0/8; p = 0.0009,
odds ratio = infinity) (Figure 2B). These data are suggestive of a
general trend of increased de novo rates and CNV size with
increased severity of the disorder.
Novel, rare CNVs reveal potential candidate genes
We then focused on rare CNVs involving single genes or regions
of potential interest. In the dyslexia cohort, two unrelated families
carried CNVs on chromosome 7q11.23 that involved the autism
susceptibility candidate 2 (AUTS2, MIM# 607270). A 669 kbp
duplication that included AUTS2 and WBSCR17 was transmitted
from an affected father to the daughter and an approximately
84 kbp deletion was transmitted from the affected paternal
grandmother through the unaffected father to the proband
(Figure 3). In addition, we also identified a 354 kbp deletion
encompassing AUTS2 in one individual with idiopathic ID,
pervasive developmental delay, partial epilepsy, and left hemihy-
pertrophy. An approximately 1.2 Mbp deletion encompassing the
eyes shut drosophila homolog gene (EYS, MIM# 612424) on
chromosome 6q12 was detected in an affected proband and
several unaffected family members. Although autosomal recessive
single-nucleotide mutations in EYS have been reported in patients
with retinitis pigmentosa [26,27], the role of heterozygous
microdeletions involving this gene is unknown.
We also identified a 471 kbp deletion involving IMMP2L
inherited by the proband from the affected mother (Figure 3).
Deletions involving IMMP2L have been associated with ADHD
[12], autism [28], and Tourette syndrome [29]. Recently,
Pagnamenta and colleagues also reported a 594 kbp IMMP2L-
DOCK4 deletion resulting in a fusion transcript and an intragenic
DOCK4 deletion segregating with dyslexia [30]. Our results are
best interpreted within the context of candidate gene identification
in dyslexia. Although at least nine chromosomal loci are associated
with dyslexia, for two of these loci the candidate genes were
identified on the basis of a rare balanced chromosomal
translocations disrupting ROBO1 [31] and DYX1C1/EKN1
[32,33]. More recently, a Danish Cytogenetic Registry study of
all cases with chromosomal translocations identified additional
novel dyslexia candidate genes affirming the value of rare
structural variants in understanding the genetics of dyslexia [34].
Our study is the first to systematically characterize rare CNVs in
dyslexia and thus evaluate the contribution of rare deletions and
duplications to this common genetic disorder.
Within the autism cohort, several novel deletions and
duplications involving neurologically-relevant genes were identi-
fied. A 5 Mbp de novo deletion involving FOXP1 on chromosome
3p14.1 was identified in an individual with features of idiopathic
autism (full-scale IQ=75). An additional 6.6 Mbp de novo deletion
overlapping FOXP1 was also identified in an individual with
idiopathic ID (Figure 4). A review of the DECIPHER database
revealed a similar-sized deletion disrupting FOXP1 in an individual
with developmental delay, sensorineural deafness, hypotonia, club
foot, and dislocation of hip. Recently, FOXP1 was implicated in
autism, ID, and language impairment [35,36,37]. It is believed
that FOXP1interacts with FOXP2 and CNTNAP2, both implicated
in speech disorders and autism [38,39]. The overlapping
1.16 Mbp region of the deletion common to both autism and
ID indicates a potential involvement of FOXP1 in pathways related
to both of these disorders. Other variants involving functionally
relevant genes include 7q36.2 deletion and duplication (DPP6),
17q23.3 duplication (SCN4A), and 17q21.32 duplication (WNT3
and WNT9B).
Our analysis of the ID cohort was enriched for singleton events
often involving genes related to developmental or neurological
functions including SYNPR, GABRA, AUTS2, FOXP1, FKBP6,
COBL, and FMR1. However, within the same cohort we were also
able to detect novel overlapping deletions (3.5 Mbp and 9 Mbp)
on chromosome 9p24 in two unrelated individuals (Figure 5A).
Both cases exhibited clinical features of ID and Pervasive
Developmental Delay-Not Otherwise Specified. The distal break-
points of these deletions map to segmental duplications while the
proximal end maps within a high density of repeat elements. A
survey of this region in the DECIPHER database [40] revealed
about 15 cases with overlapping deletions. Variable clinical
presentations and heterogeneity of deletion breakpoints preclude
Table 2. Rare CNVs in neurodevelopmental disorders.
Cohort
Total
individuals
analyzed
Number of
individuals
with rare
CNVs
Total rare
CNVs
Number of
individuals
with two
rare CNVs
RefSeq
genes
Median size
of CNV
Hotspot
CNVs
Genomic
disorder
CNVs
Dyslexia 322 6 (1.9%) 6 (1.9%) 0 (0%) 10 302 kbp 3 (50.0%) 0
Autism (with ID) 90 10 (11.1%) 11 (12.2%) 1 (10%) 445 1.62 Mbp 6 (54.5%) 5
Autism (no ID) 246 25 (10.2%) 25 (10.2%) 0 (0%) 235 633 kbp 15 (60.0%) 3
Combined Autism 336 35 (10.4%) 36 (10.7%) 1 (2.9%) 680 662 kbp 21 (58.3%) 8
Idiopathic ID 358 60 (16.8%) 64 (17.9%) 4 (6.7%) 1537 849 kbp 20 (31.3%) 15
ID (with MCA) 73 9 (12.3%) 13 (17.8%) 4 (44.4%) 678 1.86 Mbp 5 (38.5%) 5
Combined ID cohort 431 69 (16.0%) 77 (17.9%) 8 (11.6%) 2215 1.5 Mbp 25 (32.5%) 20
CNV: Copy Number Variant; ID: Intellectual Disability; MCA: Multiple Congenital Anomalies.
doi:10.1371/journal.pgen.1002334.t002
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Table 3. List of rare CNVs identified in neurodevelopmental disorders.
Chr Start End Size Chr. Band CNV Sample Cohort Type
Gene
count Inheritance
Control
count
DECIPHER
count
DGV
count
chr14 21533898 22239332 705434 14q11.2 deletion Si238 Autism_ID non HS 12 maternal 0 2 6
chr12 15036168 29977743 14941575 12p12.3p11.2 deletion Si159 Autism_ID non HS 3 de novo 0 0 0
chr15 66881730 71972563 5090833 15q23q24.1 deletion Si169 Autism_ID HS assoc 2 de novo 0 0 0
chr3 59681529 79199503 19517974 3p14.2p12.3 deletion Si163 Autism_ID non HS 3 de novo 0 0 0
chr5 175479593 175584441 104848 5q35.2 deletion Si118 Autism_ID HS 1 paternal 0 0 4
chr7 31583983 31702682 118699 7p15.3 duplication Si309 Autism_ID HS 2 maternal 0 0 2
chr16 21645311 22520339 875028 16p12.1 duplication Si247 Autism_No
ID
HS 3 NA 0 2 0
chr22 38790464 39138992 348528 22q13.1 deletion Si126 Autism_No
ID
non HS 4 de novo 0 1 0
chr3 67276200 72402720 5126520 3p14.1p13 deletion Si140 Autism_No
ID
non HS 2 de novo 0 1 1
chr1 145303997 145357746 53749 1q21.1 homozyg
deletion
Si192 Autism_No
ID
HS 0 both 0 0 0
chr1 145303997 145357746 53749 1q21.1 deletion Si85 Autism_No
ID
HS 6 paternal 0 0 0
chr11 21703096 26791696 5088600 11p14.5 duplication Si45 Autism_No
ID
non HS 0 maternal 0 0 0
chr16 72859686 72917454 57768 16p22.3 deletion Si99 Autism_No
ID
HS 5 maternal 0 0 0
chr17 15301836 16542913 1241077 17p11.2 duplication Si153 Autism_No
ID
HS 147 paternal 0 0 0
chr17 32250000 32400000 150000 17q12 duplication Si114 Autism_No
ID
HS 1 paternal 0 0 0
chr17 42115600 42437714 322114 17q21.32 duplication Si186 Autism_No
ID
HS 53 de novo 0 0 0
chr17 58889277 59561178 671901 17q23.3 duplication Si87 Autism_No
ID
non HS 1 maternal 0 0 0
chr18 69039514 69822140 782626 18q22.3 deletion Si173 Autism_No
ID
non HS 2 maternal 0 0 0
chr19 14760644 15064029 303385 19p13.12 deletion Si125 Autism_No
ID
non HS 5 maternal 0 0 0
chr2 95159338 95228560 69222 2q11.1 duplication Si226 Autism_No
ID
HS 1 de novo 0 0 0
chr20 12657983 13311383 653400 20p12.1 deletion Si20 Autism_No
ID
non HS 17 paternal 0 0 0
chr22 18562002 18748556 186554 22q11.21 duplication Si207 Autism_No
ID
HS 5 de novo 0 0 0
chr3 84868129 85439477 571348 3p12.1 duplication Si128 Autism_No
ID
non HS 73 paternal 0 0 0
chr5 370492 1003781 633289 5p15.33 duplication Si82 Autism_No
ID
HS 17 paternal 0 0 0
chr5 175504664 175584441 79777 5q35.2 deletion Si191 Autism_No
ID
HS 3 maternal 0 0 4
chr6 51096930 51899775 802845 6p12.2 duplication Si142 Autism_No
ID
non HS 4 paternal 0 0 0
chr7 152102637 153356944 1254307 7q36.2 duplication Si119 Autism_No
ID
HS 123 paternal 0 0 0
chr7 153451569 154285634 834065 7q36.2 deletion Si132 Autism_No
ID
non HS 0 maternal 0 0 0
chr1 144106777 144451305 344528 1q21.1 deletion 2602 Dyslexia HS 1 NA 2 3 0
chr3 139732796 140171095 438299 3q22.3 duplication 1806 Dyslexia non HS 142 NA 1 1 0
chr6 65179840 66364033 1184193 6q12 deletion 2803 Dyslexia non HS 1 paternal 1 1 0
chr4 123017758 123458923 441165 4q27 duplication 2286 Dyslexia non HS 0 maternal 0 0 0
chr7 40606348 40819984 213636 7p14.1 deletion 2244 Dyslexia non HS 1 maternal 0 0 0
chr7 68820751 68904999 84248 7q11.22 deletion 2867 Dyslexia HS 2 paternal 0 0 0
Large CNVs in Neurodevelopmental Phenotypes
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Chr Start End Size Chr. Band CNV Sample Cohort Type
Gene
count Inheritance
Control
count
DECIPHER
count
DGV
count
chr7 69876932 70546042 669110 7q11.22 duplication 1102 Dyslexia HS 1 paternal 0 0 0
chr7 110381300 110851860 470560 7q31.1 deletion 3437 Dyslexia non HS 102 paternal 2 0 0
chr8 11373083 11434911 61828 8p23.1 deletion 1012 Dyslexia HS 16 maternal 0 0 0
chr9 6348644 6740836 392192 9p24.1 deletion 1004 Dyslexia non HS 11 paternal 0 0 0
chr9 1 9098781 9098780 9p24 deletion 3381 ID non HS 3 de novo 0 15 0
chr11 121813520 134447248 12633728 11q24.1-q25 deletion 2597 ID non HS 33 de novo 0 15 0
chr18 1 15313807 15313806 18p11.21 duplication 2492 ID non HS 1 de novo 0 4 0
chr9 73827781 79830447 6002666 9q21.13 deletion 3413 ID non HS 1 de novo 0 4 0
chr3 196825112 197208742 383630 3q29 deletion 3331 ID HS 0 NA 0 2 1
chr6 161747330 162612669 865339 6q26 deletion 2562 ID non HS 0 maternal 0 2 0
chr6 162129914 162555946 426032 6q26 deletion 2548 ID non HS 48 paternal 0 2 0
chr9 218822 3742630 3523808 9p24 deletion 2615 ID non HS 1 de novo 0 2 0
chr3 71242809 77832202 6589393 3p13 deletion 2509 ID non HS 0 de novo 0 1 0
chr3 127000260 131353408 4353148 3q21.3 duplication 2237 ID non HS 1 NA 0 1 0
chr6 107959196 111971187 4011991 6q21 deletion 2644 ID non HS 0 de novo 0 1 0
chrX 146437800 147110597 672797 Xq27 duplication 2643 ID non HS 6 NA 0 1 0
chrY 6895278 7233586 338308 Yp11.2 duplication 2580 ID non HS 2 NA 0 1 0
chr1 76466419 77200494 734075 1p31.1 duplication 3399 ID non HS 0 maternal 0 0 0
chr1 90483825 90786224 302399 1p22.2 duplication 1799 ID non HS 48 NA 0 0 0
chr1 235537560 237086860 1549300 1q43 deletion 2518 ID non HS 2 NA 0 0 0
chr10 128662416 129042087 379671 10q26.2 deletion 1402 ID non HS 23 maternal 0 0 0
chr11 22232079 25091772 2859693 11p14.3 deletion 1613 ID non HS 2 de novo 0 0 0
chr13 95576502 96051348 474846 13q31.3q32.2 deletion 2175 ID non HS 3 NA 0 0 0
chr14 40428504 40755943 327439 14q21.1 duplication 3322 ID non HS 89 NA 0 0 1
chr15 80767738 100147041 19379303 15q25 duplication 2522 ID non HS 36 paternal or
de novo
0 0 0
chr17 34089604 34566438 476834 17q12 duplication 72 ID HS 4 NA 0 0 0
chr18 50965716 52820402 1854686 18q21 duplication 1164 ID non HS 37 de novo 0 0 0
chr19 60032498 61147051 1114553 19q13.42 deletion 3262 ID non HS 24 de novo 0 0 0
chr2 153753287 183588035 29834748 2q24.3q32.1 duplication 2559 ID non HS 5 de novo 0 0 0
chr2 188179827 188853079 673252 2q32.1 duplication 2522 ID non HS 1 paternal or
de novo
0 0 0
chr3 50846910 58424157 7577247 3p21.31p14.3 duplication 3448 ID non HS 54 de novo 0 0 0
chr3 62489781 63320060 832020 3p14.2 duplication 3445 ID non HS 413 paternal 0 0 0
chr3 137464270 137768886 304616 3q22.3 deletion 3349 ID non HS 25 NA 0 0 0
chr4 7148184 7818626 670442 4p16.1 duplication 2488 ID non HS 2 NA 0 0 0
chr4 43534966 45590689 2055723 4p13 deletion 1318 ID non HS 0 paternal 0 0 0
chr4 57346833 86106712 28759879 4q12q21.33 duplication 2154 ID non HS 2 de novo 0 0 0
chr4 152300259 152723977 423718 4q31.3 deletion 699 ID non HS 9 de novo 0 0 0
chr5 28427525 28630668 203143 5p14.1 deletion 2569 ID non HS 4 NA 0 0 0
chr5 98793016 98851760 58744 5q21.1 deletion 1519 ID HS 1 NA 0 0 0
chr5 156526018 164133824 7607806 5q33.3q34 duplication 3448 ID non HS 1 de novo 0 0 0
chr6 92767349 92988105 220756 6q16.1 deletion 3316 ID non HS 15 NA 0 0 0
chr7 45180992 45274014 93022 7p13 deletion 3296 ID HS 1 paternal or
de novo
0 0 1
chr7 51216627 51313401 96774 7p12.1 deletion 2571 ID non HS 24 NA 0 0 0
chr7 68713709 69068502 354793 7q11.22 deletion 2433 ID HS 66 NA 0 0 0
chr7 72300576 72486542 185966 7q11.23 duplication 2424 ID HS 47 maternal 0 0 0
chr7 89028789 89548951 520162 7q21.13 duplication 3352 ID non HS 42 NA 0 0 0
chr8 123404368 123637074 232706 8q24.13 deletion 3247 ID non HS 0 de novo 0 0 0
chr9 21080948 21484861 403913 9p21.3 deletion 2462 ID non HS 5 NA 0 0 0
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further genotype-phenotype correlation studies for this region
(Figure S2). We also identified a nonrecurrent 6q16 deletion (chr6:
100,383,567-103,310,184) that potentially narrows the critical
region for this recently described Prader-Willi-like syndrome [41]
to approximately 2.9 Mbp. The refined critical region contains
only five genes including the obesity-associated SIM1 [42] and the
autism-associated GRIK2 [43] (Figure 5B). About 70% of children
with 6q16 deletion manifest obesity [41]; however, our case with
the smaller deletion, encompassing SIM1, showed no evidence of
obesity at 10 years of age (Table S10).
Multiple large CNVs associate with phenotypic severity
We find that 8/69 (11.6%) cases in the ID cohort carried more
than one large, rare CNV and all of these individuals presented
with severe clinical features (Tables S6, S7, S8). A striking
difference (p = 0.008, odds ratio = 11.2) in multiple CNV rates was
also observed when the ID cohort was divided into those with
severe MCA (44%) and those with idiopathic ID (6.7%). Notable
examples are co-occurrences of a 3.4 Mbp 16p13.11 duplication
and a 3.3 Mbp deletion on chromosome 4q25 involving PITX2 in
a case with features of Rieger syndrome [44] (Figure 6) and a
17p13.3 deletion (YWHAE, Miller-Dieker syndrome) and 3q29
duplication (DLG1) in a child with cryptorchidism, ventricular
septal defect, and seizures. The 3q29 duplication is a recurrent
interstitial rearrangement [45,46] potentially mediated by flanking
segmental duplications of high sequence identity (27 kbp size, 96%
identity). The 17p13.3 deletion is a previously reported nonrecur-
rent rearrangement associated with Miller-Dieker syndrome
[47,48]. In contrast, only 1/35 (2.9%) autism cases and none of
dyslexia individuals carried another large CNV. This observation
suggests that the severity of the phenotypes can be influenced by
more than one large, rare CNV co-occurring in the same
individual. During this analysis we considered the possibility of a
derivative chromosome representing an unbalanced translocation
possibly creating the impression of multiple CNVs in our cases.
We carefully reviewed available chromosomal analysis data (G-
banded karyotyping or FISH) for each of the individuals with two
hits reported in our study. We did find one case with two hits
where apparent CNVs represent a derivative chromosome
inherited from a balanced translocation carrier parent (Table
S8D).
Discussion
Initial discoveries of significant enrichment of rare CNVs for ID
and autism led to testing the CNV basis for other behavioral and
neurodevelopmental disorders of varying population frequency
and severity, such as schizophrenia, ADHD, epilepsy, bipolar
disorder, and Tourette syndrome. However, comparisons between
these studies have been difficult due to differences in study design,
insufficient sample sizes, and lack of detailed phenotype informa-
tion. In this study, we compared 1,564 individuals (cases and
controls) on a single platform of relatively modest density with the
same type of detection bias. We utilized the duplication
architecture of the human genome to custom design a DNA
oligonucleotide microarray enriched for genomic hotspots, i.e.,
regions flanked by high-identity segmental duplications. This array
has an advantage over several other commercial arrays in that
there is a 25-fold enrichment for recurrent events in the genomic
hotspots compared to the rest of the genome [49]. Therefore,
fewer samples are required to identify several unrelated individuals
with the same pathogenic mutation. We find that our array has a
Chr Start End Size Chr. Band CNV Sample Cohort Type
Gene
count Inheritance
Control
count
DECIPHER
count
DGV
count
chr9 38634661 38791196 156535 9p13.1 deletion 3236 ID HS 0 paternal 0 0 0
chrX 28400903 28659988 259085 Xp21.3 duplication 3321 ID non HS 0 NA 0 0 0
chrX 65611216 65934000 322784 Xq12 deletion 2597 ID non HS 2 NA 0 0 2
chrX 88508702 91291323 2782621 Xq21.31
q31.32
deletion 2511 ID non HS 4 NA 0 0 0
chrY 3072083 6154525 3082442 Yp11.2 duplication 699 ID HS 2 de novo 0 0 0
chr22 40103633 41458051 1354418 22q13.2 deletion GB43 ID/MCA non HS 2 NA 0 2 0
chr4 110560125 113895249 3335124 4q25 deletion GB6 ID/MCA non HS 15 de novo 0 1 0
chr1 174979260 238257861 63278601 1q24qter duplication GB88 ID/MCA non HS 2 46,XX,t(1;5)
(q23;p15)
balanced
0 0 0
chr13 83679489 84385310 705821 13q31.1 dup duplication GB71 ID/MCA non HS 9 maternal 0 0 0
chr3 164241146 168622524 4381378 3q26.1 deletion GB42 ID/MCA non HS 11 maternal 0 0 0
chr5 90252 1630763 1540511 5p15.33 deletion GB88 ID/MCA HS 0 46,XX,t(1;5)
(q23;p15)
balanced
0 0 0
chr7 27294680 28799546 1504866 7p15.3 duplication GB65 ID/MCA non HS 23 de novo 0 0 0
chr9 201336 16672312 16470976 part
trisomy 9
duplication GB71 ID/MCA HS assoc 1 46,XX
rcp (8;10)
(q2.2;q21.2)
+t (9;12)
(p2.2;p1.3)
0 0 0
This list does not contain known genomic disorders. Please refer to Table S9 for known genomic disorders identified in this study. CNV: Copy Number Variant; ID:
Intellectual Disability; HS: Hotspot; MCA: Multiple Congenital Anomalies.
doi:10.1371/journal.pgen.1002334.t003
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comparable diagnostic yield of 16% for the ID cohort compared to
other clinical chromosomal microarray studies reported in the
literature (Figure S3).
In strong agreement with previous studies, our data suggest that
multiple, rare CNVs contribute to the etiology of autism and ID.
In contrast, we find no increase in large pathogenic CNVs in
individuals with dyslexia compared to controls. Notwithstanding,
our analysis revealed novel regions of potential relevance to the
etiology of dyslexia. Two unrelated children (2/322, 0.6%) with
dyslexia carried CNVs encompassing AUTS2, both inherited from
a parent. While the phenotype of dyslexia segregated with the
AUTS2 duplication in the first family (Figure 3A), in the second
family the deletion was inherited from affected grandmother
through unaffected father (Figure 3B). This could be due to a
phenomenon described as ‘‘compensation’’, where some adults
that reported difficulties with reading in childhood no longer
evidence signs of dyslexia [50]. Previous studies of de novo
chromosomal translocations and inversions identified breakpoints
within AUTS2 in individuals with autism and/or ID phenotypes
[51,52,53,54,55]. More recently, unique AUTS2 deletions and
duplications were observed in Juvenile Myoclonic Epilepsy [10]
and ADHD [11,12]. It is interesting to note that ADHD and
dyslexia are frequently comorbid and may have shared genetic risk
factors [56,57,58]. When our study is taken together with recent
Figure 3. Pedigree shows the inheritance of a 669 kbp duplication encompassing AUTS2 and WBSCR17 from a father to the
daughter. (A) The father has features of dyslexia with a verbal IQ (VIQ) of 122, WATTa 93, WRAT3spb 83 and WIATspc 94. The daughter’s scores are
VIQ 122, WIDd 86, WATT 91, WRAT3sp 90, and WIATsp 94. (B) In this pedigree the 84 kbp deletion within AUTS2 is transmitted to the proband (VIQ
122, WATT 97, WRAT3sp 96, WIATsp 94) from the affected paternal grandmother (VIQ 118, WATT 88) through the unaffected father. (C) A deletion
within IMMP2L is shown for this family. The deletion is transmitted to the proband (VIQ 111, WID 83, WATT 82, WRAT3sp 85, WIATsp 81) from his
affected father (VIQ 84, WRAT3sp 68, WIAT-2sp 66). Interestingly, IMMP2L variants have been associated with Tourette syndrome, ADHD, and autism.
(D) A 1.2 Mbp deletion within EYS is shown in several family members of this large pedigree. While the proband (VIQ 107, WID 56, WATT 81, WRAT3sp
87, WIATsp 87) and his affected brother (VIQ 101, WID 66, WATT 82, WRAT3sp 78, WIATsp 85) carried the deletion, so did many other unaffected
relatives, including the father. Although no inference can be drawn for its role in dyslexia, as the deletion does not segregate with the phenotype,
recessive mutations in EYS have been associated with retinitis pigmentosa. aWATT- WRMT-R Woodcock Reading Mastery Test – Revised; Word Attack
subtest [67]. A measure of untimed reading of single non-words. bWRAT3sp - Wide Range Achievement Tests – Third Addition; Spelling subtest [68].
Spelling of single words from dictation in writing. cWIAT(2)sp - Wechsler Individual Achievement Test (2nd edition); Spelling subtest [69]. Spelling of
single words from dictation in writing. dWID - WRMT-R Woodcock Reading Mastery Test – Revised; Word Identification subtest [67]. A measure of
untimed reading of single words.
doi:10.1371/journal.pgen.1002334.g003
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CNV studies of ADHD [11,12], AUTS2 CNVs were observed in
5/2,306 combined cases and 3/46,947 unscreened controls
(p = 1.1261025, odds ratio = 33.9), indicating that AUTS2 might
have an important role in pathways related to cognition. While the
function of AUTS2 is still unclear, it is strongly expressed in fetal
and adult brains, particularly in the frontal, parietal, and temporal
lobes [59]. Interestingly, AUTS2 and the 7q11.2 region were
identified as having the strongest statistical signal for positive
selection in early modern humans as compared to the Neanderthal
genome [60], indicating that AUTS2 might be important for a
specialized human function such as cognition.
The CNV profile we observed in individuals with dyslexia was
essentially the same as that in control individuals. This is not
surprising if we take into consideration that all the subjects in our
dyslexia sample had a VIQ above the 25%ile and the mean VIQ
of the cohort was 110 (2/3 standard deviations above the general
population mean), and given that we have shown that the CNV
profile correlates with the severity of ID. The genes involved in
dyslexia are likely to affect more specialized cognitive functions,
may not adversely affect general intelligence, and may be more
amenable to discovery with high-density arrays capable of
detecting single gene or single exon CNVs or SNP microarrays
that can leverage SNP allele frequency information in addition to
signal intensity. In addition, all hybridization-based platforms fail
to detect copy number neutral changes, such as balanced
chromosomal rearrangements and inversions. This is particularly
germane to dyslexia where a large number of candidate genes
have been identified through mapping of translocation breakpoints
[21,34].
A comparison of rare de novo CNV rates for autism shows that
our estimates (4%, 14/336) fall within a range of 4–10% reported
previously by other large-scale, high-density array studies
[4,61,62,63]. This suggests that no platform-specific bias exists
for large variants and also that the contribution of large CNVs is
consistent across all studies for autism. We find a significantly
greater enrichment for large CNVs, higher de novo rates, and a
higher frequency of two rare CNV hits in individuals with ID-
associated phenotypes compared to autism or dyslexia. This
observation is exemplified by the fact that individuals with autism
with ID have more large CNVs than those with autism only. We
also find a significant difference between individuals with autism
versus those with dyslexia. Sanders and colleagues recently
analyzed 1,124 SSC families affected with autism spectrum
disorder (ASD). Using stepwise linear models, they evaluated the
relationship between intellectual functioning, sex, and the number
of genes within rare, de novo CNVs. While the number of genes
affected correlated with the size of the de novo CNV, the authors
did not find a strong correlation of the Autism Diagnostic
Observation Schedule (ADOS) combined severity score (p = 0.25,
R2= 0.005) or full-scale IQ (p= 0.02, R2= 0.08) with the size of
the CNV. In contrast, we considered all large CNVs (common and
rare, de novo and transmitted) identified in a relatively smaller
sample size and essentially bifurcated the autism cohort using a
full-scale IQ score cutoff of 70. There was also a greater
enrichment of two hits in the ID cohort (11.6%) compared to
the autism cohort (2.8%). In fact, one individual carrying a
16p11.2 deletion with autism and features of ID also has a
maternally inherited 22q11.2 duplication (TBX1) providing further
evidence for the two-hit hypothesis we previously proposed for
severe developmental delay [64]. Further, the frequency of two
hits was even more striking when only individuals with ID/MCA
were considered (44%), albeit the number of cases is few. We
believe these data provide support for an incremental effect of
CNV size and number on the severity of phenotypic outcome.
Our experimental design is biased towards interrogating hotspot
regions in the human genome. A comparison to recently reported
Figure 4. FOXP1 deletions in individuals with autism and ID. Two deletions (5 Mbp and 6.6 Mbp) are shown intersecting at a common region
of 1.16 Mbp containing FOXP1. Note that the deletion in the autism individual also covers ROBO2 and CNTN3.
doi:10.1371/journal.pgen.1002334.g004
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studies [61,63] suggests that the majority of false-negative calls will
reside within non-hotspot regions due to a lack of probe coverage
(,10 probes). While the detection power of our array increases
with the size of the variant, we would certainly miss smaller and
intragenic CNVs, for example in autism candidate genes such as
NRXN1 [65,66], CACNA1C, SLC4A10, MAGI1 [63], SYNGAP1,
DLGAP2 [62], NLGN1, ASTN2 [67], and exonic copy number
variants in ASPM, DPP10, CNTNAP2, A2BP1, PCDH9 [68], and
PTCHD1 [69]. While we find no excess of large CNVs in dyslexia,
there is still the possibility that large CNVs are relevant in some
familial cases of the disease as well as occasional sporadic cases.
Further studies are warranted for a more detailed analysis of all the
three neurodevelopmental cohorts using high-resolution arrays
and next-generation exome and/or whole-genome sequencing.
Figure 5. Novel CNVs identified in the ID cohort. (A) Overlapping deletions on chromosome 9p24 are shown. Deletions of this region
containing DMRT1 and DMRT3 have also been associated with urogenital abnormalites and sex reversal. (B) A ,3 Mbp deletion on 6q16 is shown
encompassing SIM1. Larger deletions of this region were previously reported and have been associated with obesity. Orange bars denote deletions
and gray regions are non-deleted regions from previous studies [41]. Taken together with other published studies, this deletion narrows down the
critical region (dotted box) to about 2.9 Mbp.
doi:10.1371/journal.pgen.1002334.g005
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While it can be difficult to compare data derived from different
microarrays, there is value to multiple array platforms and cross-
platform validation. The depositing of the resulting data into
publicly available databases will facilitate the continued elucida-
tion of recurring clinically significant CNV and genotype-
phenotype correlations.
Materials and Methods
Ethics statement
Patients from each of study cohort were recruited after
appropriate human subjects approval and informed consent.
Informed consent was also obtained to publish photographs.
Patient ascertainment based on severity of phenotypes
DNA samples were obtained from cases ascertained for three
neurodevelopmental disorders of varying severity: (1) ID/devel-
opmental delay and MCA, (2) dyslexia or reading impairment,
and (3) idiopathic autism. We defined severity of clinical features
based on presence or absence of ID (IQ,70) for the autism group
and congenital malformation for the ID group. Our dyslexia
cohort had no ID or congenital malformation cases; as an IQ#90
and the presence of congenital malformations were exclusion
criteria. Individuals with idiopathic autism were partitioned into
those with autism and ID (IQ,70) and those without ID (IQ.70).
For the ID cohort, those individuals with brain malformations,
gross craniofacial dysmorphology, cardiac defects, and neurolog-
ical deficits were separated into an ID plus MCA (ID/MCA)
group. Thus, in the order of severity, the ID/MCA cohort is
considered the most severe, followed by ID only, autism with ID,
autism without ID, dyslexia, and normal controls. However, we
note that although the individuals with dyslexia do not have ID,
they have severe impairments in core phonological measures
leading to significantly reduced reading abilities despite normal IQ
(IQ$90). Detailed descriptions of each of the cohorts are given
below.
Ascertainment of individuals with dyslexia or reading
disability
For the dyslexia subject set, children were considered eligible for
the study if they met researcher-defined criteria based on test
scores from a standardized battery of tests. DNA samples were
Figure 6. Two large CNV hits in a case with ID/MCA. A 3.3 Mbp deletion containing PITX2 as well as the 3.4 Mbp paternally inherited 16p13.33
duplication is shown for an individual with ID plus MCA. This individual has features of Rieger syndrome including visual defects, mild hypotonia,
right congenital glaucoma, left microophalmia, and anterior segment dysgenesis. Other features include cleft uvula, hypodontia and conical teeth,
hyperplasia of frenulum of tongue, midface hypoplasia, strabismus, and deafness.
doi:10.1371/journal.pgen.1002334.g006
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obtained from two cohorts. The first cohort included probands
aged 6 to 16 from 198 families who were initially ascertained at the
University of Washington (UW) multidisciplinary Learning
Disability Center (UWLDC) under protocols approved by the
UW Institutional Review Board. For the UWLDC cohort,
probands were required to have a prorated VIQ at or above 90
($25%ile) on the Wechsler Intelligence Scale for Children – 3rd
edition [13], with performance below the age-specific population
mean and at least one standard deviation below the VIQ on one
or more out of 10 research measures of reading, writing, or
spelling. As a group, on average, probands met the impairment
criteria between 6 and 7 measures. As expected by ascertainment
requirements, the average VIQ of probands in this cohort was 110
($75%ile) [70,71]. Siblings older than 6.5 years were invited to
participate, and additional family members were added using a
sequential sampling strategy to extend pedigrees through family
members with the most extreme impairment values on the same
10 research measures. Detailed recruitment and evaluation
procedures for the UWLDC cohort were described earlier
[50,72] (see Table S4A).
For the second cohort, 178 children aged 5 to 12 were recruited
from a special K-6 school for students with dyslexia or via their
direct relatives in the Atlanta area (The Schenck School, Atlanta,
GA). For this cohort, children were required to have a
psychological battery of tests completed by a licensed psychologist
and usually have a diagnosis of a reading disability. Based on
strong verbal comprehension score, perceptual reasoning score,
Peabody picture vocabulary test, or other cognitive tests that
measure intelligence, these children have average to above-
average intelligence. Both cohorts were composed of individuals
with .90% Caucasian ethnicity with an approximately equal
number of males and females. Except for ADHD, children with
other psychiatric and neurological disorders, moderate to severe
receptive language disorders, developmental disabilities, or other
conditions known to affect cognition were excluded based on
parental questionnaire. Clinical details are shown in Table S4B.
Ascertainment of individuals with features of autism with
or without ID
For the autism cohort, families were identified through the SSC
(www.sfari.org) [73]. The Simons Foundation-funded SSC
includes families with no more than one child with autism
ascertained through 12 data collection sites across North America.
Of the 350 individuals included in this study 297 (85%) are of
Caucasian ethnicity. Inclusion criteria in the collection requires
that the child with autism meet ASD criteria on the ADOS [74],
on the Autism Diagnostic Interview, Revised (ADI-R) [75], and
meet expert clinical judgment. Nonverbal IQ estimate must also
be greater than 35. Children with significant hearing, vision, or
motor problems, significant birth complications (e.g. extended
NICU stay), or with a diagnosis of ASD-related disorders, such as
Fragile X, were excluded. Children with a relative (up to third
degree) with ASD or sibling who showed ASD-related symptoms
were also excluded. Diagnostic evaluations, cognitive assessment,
and phenotypic characterization were conducted at each site with
data collection, data entry, and data validation methods
standardized across sites to ensure reliability of sample collection.
We further partitioned the autism cohort into those associated
with ID (average full scale IQ=49) consisting of 97 cases (73
males, 24 females; median age, 12 years) and those without ID
(average full scale IQ=98.9) comprising 253 cases (228 males, 25
females; median age, 11 years and 11 months). Clinical details are
shown in Table S5.
Ascertainment of individuals with intellectual disability
with or without congenital malformation
The idiopathic ID cohort was selected from individuals
admitted to the IRCCS Associazione Oasi Maria Santissima and
screened for ID according to the Diagnostic and Statistical Manual
of Mental Disorders-IV-Text Revision (DSM-IV-TR) criteria.
This cohort consists of 428 cases (153 females, 275 males; median
age, 15 years) of Caucasian ethnicity with idiopathic ID and
previously excluded for common causes of ID, including Fragile X
syndrome, trisomies 21 and 13. In addition, classical genomic
syndromes such as Smith-Magenis, DiGeorge, Prader-Willi/
Angelman, and Williams syndromes, if recognized by clinical
evaluation, were followed up for confirmation using targeted
multiplex ligation-dependent probe amplification and excluded.
We note that cases with phenotypic variability that escape clinical
detection might not have been excluded. Typically, idiopathic
cases of ID with no classical constellation of clinical features
suggestive of a known disorder or those with mild to moderate ID
without significant congenital malformation were included in this
cohort. Clinical details are shown in Table S6.
Individuals with features of ID with MCA not necessarily
assigned to a specific syndrome were evaluated and recruited at
the University of Torino. This cohort consists of 73 individuals (32
females and 41 males) of Caucasian ethnicity with a median age of
2 years at diagnosis. Clinical features of these individuals included
brain malformations, craniofacial dysmorphology, and neurolog-
ical deficits along with variable ID (Table S7). Informed consent
was obtained from all the subjects included in both the studies.
Ascertainment of normal controls
The control cohort consisted of 337 DNA samples obtained
from the Rutgers University Cell and DNA Repository (www.
rucdr.org). These individuals were ascertained by the NIMH
Genetics Initiative [76] through an online self-report based on the
Composite International Diagnostic Instrument Short-Form
(CIDI-SF) [77] and screened specifically for eight mental health
disorders, including major depression, bipolar disorder, and
psychosis, but were not screened for dyslexia and therefore not
ideal for such comparisons. Those who did not meet DSM-IV
criteria for major depression, denied a history of bipolar disorder
or psychosis, and reported exclusively European origins were
included [78,79].
Additionally, CNV data from 8,329 additional cell line and
blood-derived controls were used to assess the frequency of our
putative pathogenic CNVs in a larger population of neurologically
normal individuals. These data were derived primarily from
genome-wide association studies of non-neurological phenotypes.
Although these data were not ascertained specifically for
neurological disorders, they consist of adult individuals providing
informed consent. Specifically, datasets from the following sources
were included in our analysis: Human Genome Diversity Project
[49,80]; National Institute of Neurological Disorders and Stroke
(NINDS) (dbGaP accession no. phs000089) [49,81]; Pharmacoge-
nomics and Risk of Cardiovascular Disease (PARC/PARC2)
[82,83]; parents of asthmatic children courtesy of Stephanie
London [49]; Fred Hutchinson Cancer Research Center (prere-
lease data provided courtesy of Aaron Aragaki, Charles Kooper-
berg, and Rebecca Jackson as part of an ongoing genome-wide
association study to identify genetic components of hip fracture in
the Women’s Health Initiative); InCHIANTI (data provided by
InCHIANTI study of aging, www.inchiantistudy.net) [49,84]; and
the Wellcome Trust Case Control Consortium phase 2 (National
Blood Service) [7]. All samples were genotyped on Illumina arrays
using methodology described previously [49] [85] and either
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natively processed in hg18 or re-mapped after CNV calling
(NINDS and PARC) to hg18 using the UCSC LiftOver tool
(http://genome.ucsc.edu).
Array CGH and analysis
We designed custom targeted hotspot v1.0 arrays comprised of
135,000 probes (by Roche NimbleGen) with higher density probe
coverage (median probe spacing 2.6 kbp) in the genomic hotspots
(regions flanked by segmental duplications) and a lower probe
density in the genomic backbone (median probe spacing 36 kbp).
All microarray hybridization experiments were performed as
described previously [86], using a single unaffected male
(GM15724 from Coriell) as reference. All validation experiments
were performed using two custom array designs: (1) a custom
targeted 46180 K Agilent chip with median probe spacing of
2 kbp in the genomic hotspots and whole-genome backbone
coverage of one probe every 36 kbp (Agilent Technologies) and (2)
a custom targeted 36720 K NimbleGen or 26400 K Agilent chip
with median probe spacing of 500 bp in the genomic hotspots and
probe spacing of 14 kbp in the genomic backbone.
All arrays were analyzed by mapping probe coordinates to the
human genome assembly Build 36 (hg18). Using chromosome-
specific means and standard deviations, normalized log intensity
ratios for each sample were transformed into z-scores. These z-
scores were then classified as ‘‘increased’’, ‘‘normal’’, or ‘‘de-
creased’’ in copy number using a three-state HMM. The HMM
was applied using HMMSeg [87]. For each sample, HMM state
assignments of probes were merged into segments if consecutive
probes of the same state less than 50 kbp apart. If two segments of
the same state were separated by an intervening sequence of #5
probes and #10 kbp, both segments and intervening sequence
were called as a single variant. Further, we employed stringent QC
measures and empirically estimated post-HMM filtering thresh-
olds (absolute z-score .1.5 and .10 probes) to increase the
specificity of our experiments. With these filtering criteria, we were
able to thoroughly scan HMM outputs for CNV events and
manually check the validity of each call by examining the
normalized log intensity ratios across a chromosome. For the
Agilent arrays, data analysis was performed following feature
extraction using DNA analytics with ADM-2 setting according to
the manufacturer’s instructions. All CNVs calls were visually
inspected in the UCSC genome browser.
First, we carried out validation on 24 samples from the
developmental delay cohort and confirmed 117/118 HMM-inferred
calls with a validation rate of 99.15%. Next, we validated 84 CNVs
from an independent set of cases both validated using fluorescence in
situ hybridization (FISH) and locus-specific custom high-density arrays
[64] (Girirajan and Eichler, unpublished). We also validated all 44
calls from the autism cohort, 22 calls from the dyslexia cohort, and 78
calls from the developmental delay cohort. In addition, in an analysis
of 517 individuals with epilepsy using this array design, 61/63 CNVs
were validated on a different array platform [10].
Supporting Information
Dataset S1 CNV calls in autism.
(XLSX)
Dataset S2 CNV calls in ID.
(XLSX)
Dataset S3 CNV calls in NIMH controls.
(XLSX)
Dataset S4 CNV calls in dyslexia.
(XLSX)
Figure S1 Probe densities and CNV detection threshold of hotspot
v1 chip. Although the median density of the chip was designed to be
approximately 2.6 kbp in the genomic hotspots and 36 kbp in
genomic backbone, the limitations of the chip design (probe
assignment restricted to only up to five mismatches) precluded
uniform distribution of the probes throughout the genome. Therefore,
the actual probe density varied across regions of the human genome.
(a) The plot shows the size-wise distribution of CNVs and the density
of array probes targeted to the genomic hotspots and non-hotspot
regions. Note that non-hotspot regions contain two different probe
densities (probe spacing of 20,000 bp and about 30,000 bp labeled a
& b) and the hotspots (shaded) are covered every 10,000 bp. (b) The
histogram shows the CNV detection threshold for the hotspot v1 chip.
The data represent all the CNV calls obtained from analyzing cases
with intellectual disability (ID). The number of CNVs detected in the
aggregate at different size thresholds is shown on the Y-axis. We
utilized a threshold of .10 probes, .1.5 z-score, and .50 kbp for
CNV detection analysis. While we were easily able to detect events
.50 kbp in the hotspot regions, we were only able to call variants
ranging from 150 kbp (hotspot-associated CNVs) and 300 kbp
onwards (mostly non-hotspot CNVs) with confidence (i.e., able to
validate) for the non-hotspot regions.
(PDF)
Figure S2 Comparison of 9p24 deletions identified in our study to
DECIPHER database. The figure shows genome browser snapshot
of the 9p24 region with red and blue bars denoting deletions and
duplications respectively in the DECIPHER database. Major
clinical features observed in these patients are also shown. Please
note that the black bars at the top denote CNVs identified in our
study. PDD-NOS, Pervasive developmental delay-not otherwise
specified; ID/DD, intellectual disability/developmental delay.
(PDF)
Figure S3 Diagnostic yield of different microarray reports from
literature. Histograms show the number of rare CNVs (usually
disease-associated) observed under different diagnostic centers.
Data is shown for sample sizes .50. Data obtained from Table 2
of Miller et al., AJHG.
(PDF)
Table S1 Chromosomal regions and probes targeted in the
hotspot chip. List of all regions targeted in the hotspot chip. The
list is derived from the original curation of segmental duplication
regions and genomic hotspots from Bailey et al, 2002 [14].
(PDF)
Table S2 Confirmation of CNVs arrays using custom high-
density arrays. Validation of CNVs identified using NimbleGen
hotspotv1 arrays (126135 K) using a higher density 36720K
NimbleGen or 26400K Agilent arrays.
(PDF)
Table S3 Global analysis for CNVs in neurodevelopmental
disorders. Summary and characteristics of deletions and duplica-
tions identified in the four cohorts studied.
(PDF)
Table S4 (A) Characteristics of dyslexia cases from UW.
Dyslexia measurements and scores of children tested at the UW.
WATT- WRMT-R Woodcock Reading Mastery Test – Revised;
Word Attack subtest. A measure of untimed reading of single non-
words. WRAT3sp - Wide Range Achievement Tests – Third
Addition; Spelling subtest. Spelling of single words from dictation
in writing. WIAT(2)sp - Wechsler Individual Achievement Test
(2nd edition); Spelling subtest. Spelling of single words from
dictation in writing. WID - WRMT-R Woodcock Reading
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Mastery Test – Revised; Word Identification subtest. A measure of
untimed reading of single words. (B) Characteristics of dyslexia
cases recruited from Atlanta. Gender, phenotype and age of
children recruited from the Atlanta collection is shown.
(PDF)
Table S5 Clinical details of cases with autism (both with and
without ID). Clinical features of individuals recruited through the
Simons Simplex Collection (n = 350) are shown.
(PDF)
Table S6 Clinical details of cases with idiopathic ID. Clinical
features of individuals with ID are shown. These individuals were
recruited and evaluated at the IRCCS Associazione Oasi Maria
Santissima, Troina.
(PDF)
Table S7 Clinical features of cases with ID plus MCA.
Presenting clinical features, additional malformations, and pre-
liminary cytogenetic and genetic evaluations performed for these
cases are shown.
(PDF)
Table S8 (A) Comparison of rare CNV rates in the cohorts
studied. (B) Rare CNVs in dyslexia, autism, and ID. (C)
Inheritance of rare CNVs in the disease cohorts. (D) Individuals
with two rare copy number variants (two hits).
(PDF)
Table S9 Genomic disorders identified in 1,227 cases with ID,
autism, and ID/MCA. Genomic disorders are defined as copy
number variants that are previously identified to be associated
significantly in individuals with disease compared to controls.
These CNVs can either map within genomic hotspot (HS) or non-
hotspot regions (non-HS).
(PDF)
Table S10 Clinical features of a case with 6q16 deletion.
Comparison of clinical features from published sources with those
in the current study.
(PDF)
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